日本黄色小说视频,日韩在线一区二区三区免费视频,亚洲电影在线,精品欧美日韩一区二区三区,久久香蕉国产线看观看亚洲卡,美女浴室,美女脱衣诱惑

    3月24日，美國(guó)食品與藥物管理局（FDA）警告，抗心律失常藥物胺碘酮與丙肝抗病毒治療藥物ledipasvir/sofosbuvir（Harvoni）或sofosbuvir（Sovaldi）同時(shí)應(yīng)用時(shí)可導(dǎo)致患者癥狀性心動(dòng)過(guò)緩。該警告內(nèi)容將會(huì)被加入相應(yīng)藥物的說(shuō)明書(shū)中。FDA也將繼續(xù)調(diào)查這種心臟事件的原因。

    信息原文：

    FDA Warns Against Combination of Hepatitis C Treatment and Antiarrhythmic Drug | ACC News StoryOn March 24, the U.S. Food and Drug Administration （FDA） issued a warning against taking the antiarrhythmic drug amiodarone in combination with hepatitis C drug treatments and another direct acting antiviral.

    In their announcement, the FDA stated that amiodarone “taken together with either the hepatitis C drug Harvoni （ledipasvir/sofosbuvir） or with Sovaldi （sofosbuvir）， taken in combination with another direct acting antiviral for the treatment of hepatitis C infection” can cause symptomatic bradycardia. The warning will be added to the labels of Harvoni and Sovaldi, and the FDA will continue to investigate the cause of the heart-related events.